a focus on RAAS inhibition and management of hyperkalaemia
This webinar is supported by Vifor Pharma UK with an unrestricted educational grant.
What is the webinar about?
We have been listening to your feedback that you would like more case-based and practical learning so we are delighted to be able offer this new webinar, led by experts in the field, that will discuss the practical approach to the management of hyperkalaemia in patients with cardiorenal disease.
This will include the approach to broad-spectrum presentations, from those with potentially life-threatening hyperkalaemia through to the impact of high potassium on the use of prognostically important renin-angiotensin-aldosterone system (RAAS) inhibitors. Using case examples, they will discuss and guide on how to optimally manage such patients and avoid pitfalls that might have adverse consequences. Wherever possible, local pathways will be used and multidisciplinary discussion encouraged.
Learning objectives
At the end of the webinar, delegates will have learned/contributed to multidisciplinary discussion around the following topics:
Is it for me?
This webinar is intended for healthcare professionals. It is aimed at anyone treating the cardiorenal patient particularly those working in heart failure, cardiology, nephrology, care of the elderly, general medicine, general practitioners, clinical pharmacists and allied disciplines.
Accreditation
The Royal College of Physicians have endorsed this webinar for 2 CPD points. Participants accessing this archived version of the webinar may record this in their CPD diary using the approval code 133114 for up to four weeks after the live event (i.e. up to 19 November 2020).
Endorsements
We are delighted that KDIGO (Kidney Disease Improving Global Outcomes) has endorsed this webinar.
Ms Carys Barton |
|
Ms Janine Beezer |
|
Dr Patricia Campbell |
Professor Paul Kalra |
|
Professor Philip Kalra |
|
Dr Kieran McCafferty |
Funding
This webinar is supported by Vifor Pharma UK with an unrestricted educational grant.